



**UNIKLINIK
KÖLN**

**29th January 2018
BRCA Tumour Testing
Masterclass - Jerusalem**



**Review of methodologies for tumor testing;
highlighting experience
from University Hospital Cologne**

29.01.2018 | Carina Heydt



- How to conduct *BRCA* tumour testing:
 - Preparation of tissue for testing (Macro-dissection, DNA extraction & quantification)
 - Review of available methodology
 - Demonstration of commercial kits and equipment
 - Sequencing
 - Factors which may influence your choice of methodology/kit/equipment
 - Ensuring a good quality test/ result



Is it possible to use your existing
germline process for sporadic
tumour material?

Germline mutation

- Present in all body cells
- heterozygous
- Can be inherited
- Cause cancer family syndrome
- >50% Allele frequency of mutation



<http://www.selectscience.net>




<http://www.minalevidds.com>

Somatic mutation

- Occur in tumour tissue only
- Cannot be inherited
- Allele frequency of mutation depends on percent of tumour cells (>10%) and normal cells
- Mutation detection depends on quality of tumour material (FFPE)



Standard in Pathology



<http://www.braintumour.ca>




How is the tissue prepared for
DNA extraction?

- Buffered formalin is essential
- Examining haematoxylin and eosin (HE) stained slide
- Highlighting the tumour area precisely
- Little as possible normal cells should be included
- Somatic mutations occur in tumour tissue only
- Pen should be indelible
- Estimating of tumour cell content (Ratio normal/tumour cells)
- At least 10-20% depending on method used





Tumour area and tumour cell percentage estimated by three different pathologists



- Three to nine 10 μm thick slides depending on size of tumour area
- Avoid cross contamination between samples
- Use fresh blade for each tissue block
- Clean water bath







Institute B



Institute C

Platform	EGFR mutation status	allele frequency %	DNA conc. (ng/μl)
Institute B	19: c.2236_2250del p.E746_A750del	14	17,32
Institute C	19: c.2236_2250del p.E746_A750del	54	3,78



How is the DNA extraction step
conducted?

Automated systems




QIAcube (Qiagen)



QIASymphony SP (Qiagen)



Maxwell 16 (Promega)





InnuPure C16 (Analytik Jena)

Manual kits


- QIAamp DNA FFPE Tissue Kit (Qiagen)
- RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific)
- ReliaPrep™ FFPE gDNA Miniprep System (Promega)
- Custom FFPE DNA extraction methods

and many more


- automated DNA extraction on different devices leads to different yields
- important for the extraction of small biopsies (up to 75% of cases in lung cancer diagnostics)




Performance of single-plex PCR:




Performance of multi-plex PCR:





⇒ transition **G>A**



⇒ transition **T>C**

- formalin fixation leads to DNA artefacts by deamination
- Deamination of cytosine leads to uracil, deamination of adenine to hypoxanthine
- Wrong bases are incorporated during PCR
- Look like point mutation
- All types of transition may occur: C>T, G>A, A>G, T>C



- Buffered formalin is essential
- Precise highlighting of tumour area on HE stained slide by pathologist
 - Varying tumour cell content, for NGS >10%
 - Mutations in tumour cells only
- Exact macrodissection of tumour area with scalpel
- You have to avoid cross-contamination during section cutting with a microtome and during macrodissection with other samples
- Complete deparaffinization and lysis
- Use the system that give the highest DNA quality and quantity and best results in downstream applications
- Avoid too high salt concentration in DNA solution
- You have to keep in mind that:
 - Formalin leads to artefacts by deamination (G<>A and C<>T artefacts)
 - FFPE DNA is mostly highly fragmented
 - Varying quality of FFPE material depending on tissue degradation and appropriate formalin fixation



Is there a minimum amount of DNA
needed to continue to the next
step?

- **UV absorbance**

- NanoDrop® (Thermo Fisher Scientific)



- **Fluorescent dye-based quantification**

- Qubit® 2.0/3.0 Fluorometer (Thermo Fisher Scientific)
- Quantus™ Fluorometer (Promega)
- Quant-iT™ PicoGreen® dsDNA Assay (Thermo Fisher Scientific)



- **qPCR (custom primers)**

- SsoFast™ EvaGreen® Supermix (BioRad)

- GoTaq® qPCR Master Mix (Promega)



- **qPCR (commercially available)**

- GeneRead DNA QuantiMIZE Kit (Qiagen)

- KAPA hgDNA Quantification and QC Kit (KapaBiosystems)

- TruSeq FFPE DNA Library Prep QC Kit (Illumina)

- Agilent NGS FFPE QC Kit (Agilent)



Manufacturers of FFPE tumour testing assays mostly advice you which DNA quantification you should use with their assay.



NanoDrop™ 2000c Spectrophotometer

2	3	4	5	6	7	8	9	10	11	12	15	16	+	-	- 1000 bp
															- 275 bp
															- 0 bp

Qubit® 2.0 Fluorometer

2	3	4	5	6	7	8	9	10	11	12	15	16	+	-	- 1000 bp
															- 275 bp
															- 0 bp

Quant-iT™ PicoGreen® dsDNA Reagent

2	3	4	5	6	7	8	9	10	11	12	15	16	+	-	- 1000 bp
															- 275 bp
															- 0 bp

QuantiFluor™-ST Fluorometer

2	3	4	5	6	7	8	9	10	11	12	15	16	+	-	- 1000 bp
															- 275 bp
															- 0 bp

qPCR

2	3	4	5	6	7	8	9	10	11	12	15	16	+	-	- 1000 bp
															- 275 bp
															- 0 bp

- 20 ng DNA extracted with the Maxwell system and determined with each of the measurement techniques of were amplified

⇒ no difference in amplification

⇒ the same is true for multiplex PCR



What are the factors involved in
choosing a tumour *BRCA* assay?


- **Whole genome** = too much information
 - difficult regions, e.g. repetitive regions, cannot be avoided
 - costs are high, not suited for bench-top systems
 - extensive bioinformatics needed for evaluation and data storage

HQ
DNA
- **Whole exome** = exons and adjoining splice-sites
 - no complete coverage of all gene regions
 - some fusions can't be detected


HQ and
HQ FFPE
DNA
- **Targeted sequencing** = gene panel
 - defined target regions
 - PCR-based or hybridization-based enrichment
 - detection of gene fusions and copy number changes is possible

HQ and
FFPE
DNA

BRCA1:
24 Exons



BRCA2:
27 Exons



Nature Reviews | Cancer

- Two large genes
- All positions are relevant for tumour testing

PCR-based (Qiagen)


Hybridization-based (Agilent)

4 x ≤10 ng


Multiplex PCR
Fragments: 125 – 175 bp

> 50 ng

Sonification
Fragments: ~150 bp




DNA-Extraction
↓
DNA-Quantification



End-Repair



Adenylation



Adapter ligation

2. PCR (1. PCR): ~10 Cycles

Library-Quantification



Fragments: 250 - 300 bp

Enrichment



MiSeq™ System (Illumina)

Hybridization of biotinylated probes to targeted regions.
Enrichment using streptavidin beads.



PCR-based

- Less chemicals required
- No DNA fragmentation required
- Faster and cheaper
- More robust and easy
- Data interpretation easier
- Assays for FFPE Material available
- Low DNA input

- Multiplexing is limited
- Polymerase read errors
- Amplification of FFPE fixation artefacts
- Duplicate reads
- Can not detect fusion events
- Detection of copy number changes might be difficult

Hybridization-based

- Easier to add new targets
- 1 panel for all entities
- Detection of gene fusions and complex events
- Fixation artefacts are avoided
- Less rounds of amplification
- Better duplicate filtering

- Expensive and complex procedure and data interpretation
- Not specifically designed for FFPE material
- Higher DNA input (>50 ng)
- 20% of samples have <50 ng of DNA
- Strong bias with LQ FFPE DNA
- Use of larger Benchtop-Sequencer like NextSeq 500

PCR-based

- Less chemicals required
- No DNA fragmentation required
- Faster and cheaper
- More robust and easy
- Data interpretation easier
- Assays for FFPE Material available
- Low DNA input

- Multiplexing is limited
- Polymerase read errors
- Amplification of FFPE fixation artifacts
- Duplicate reads
- Can not detect fusion events
- Detection of copy number changes might be difficult

Hybridization-based

- Easier to add new targets
- 1 panel for all entities
- Detection of gene fusions and complex events
- FFPE material
- Low DNA input
- Benchtop

- Exome capture and
- Next generation sequencing
- High throughput
- 200-500 Mb
- Standard

- Use of larger Benchtop-Sequencer like NextSeq 500

Usable with FFPE material

- SureSelect XT (HS) (Agilent)
- TruSight Exome (Illumina)
- TST170 (Illumina)

and more

Commercial Kits

- Ion AmpliSeq™ *BRCA1* and *BRCA2* Panel or OncoPrint *BRCA* Research Assay (Thermo Fisher Scientific)
- *BRCA* tumor MASTR plus Dx (Multiplicom - Agilent)
- TruSeq Amplicon - *BRCA1* and *BRCA2* (Illumina)
- Archer VariantPlex *BRCA* assays (Archerdx)
- GeneRead DNAseq Targeted Panel V2 - Human *BRCA1* and *BRCA2* Panel (Qiagen)
- QIAseq Targeted DNA Panel (V3 Chemistry) - Human *BRCA1* and *BRCA2* Panel (Qiagen)

Lab Developed Assays

- Targeted sequencing using smMIP (molecular inversion probes)¹
- Other lab developed NGS sequencing assays



How is the GeneRead library from
Qiagen prepared and constructed?

- **Multiplex PCR:**

- GeneRead DNaseq Targeted Panel V2 - Human *BRCA1* and *BRCA2* Panel (NGHS-102X)
- GeneRead DNaseq Panel PCR Reagent V2



- **Library Prep:**

- GeneRead DNA Library I Core Kit (for Illumina)
- GeneRead DNA I Amp Kit (for Illumina)
- Nextflex-96™ DNA Barcodes (96 Barcodes for Illumina - BIOO Scientific)



Or




GeneRead DNA Library I Kit (96) including 96 Barcodes for Illumina (Qiagen)

Or

QIAseq 1-Step Amplicon Library Kit (96) including 96 Barcodes for Illumina (Qiagen)

Library Preparation


DNA quantification by
qPCR + Multiplex PCR






How are other PCR-based libraries prepared and constructed?

Thermo Fisher Scientific





<https://www.thermofisher.com/>

Multiplicom (Agilent)



- Multiplex PCR of target regions
- Removal of PCR duplicates not possible
- Fixation artefacts cannot be distinguished from real mutations
- No Molecular Barcodes




- Hybridization of Cancer Panel oligonucleotide probes
- Dual strand sequencing allows easy differentiation of damage artifacts from FFPE treatment from true somatic mutations.
- No molecular barcodes


→ Low frequency variant detection, removal of PCR duplicates → unique reads

Library generation


STEP 1 - Barcoding



STEP 2 - Amplification



Consensus sequence generation




random barcode mix unique barcodes sequencing adaptors

- HaloPlex – Agilent
- MBC Adapter – Archer
- QiaSeq Targeted Panels – Qiagen

http://www.imgm.com/images/imgm/ScientificOverview/MGx-Overview_Bild-LEA-Seq.png


Archer Variant Plex



<http://archerdx.com/home/workflow>

- Single Primer extension
- Molecular Barcodes
- Removal of PCR duplicates and fixation artefacts

QIAseq (Qiagen)



<http://www.qiagen.com>



Which devices and methods can be used for the different quality checkpoints during your library preparation?



2100 Bioanalyzer Instruments (Agilent)



4200 TapeStation instrument (Agilent)

Or
conventional
agarose gels




QIAxcel Advanced System (Qiagen)




Fragment Analyzer™
(Advanced Analytical Technologies)


Has the PCR worked?



Has the library worked?



Multiplex-PCR



- **Fluorescent dye-based quantification**

- Qubit® 2.0/3.0 Fluorometer (Thermo Fisher Scientific)

- Quantus™ Fluorometer (Promega)

- Quant-iT™ PicoGreen® dsDNA Assay (Thermo Fisher Scientific)



- **qPCR (custom primers)**

- SsoFast™ EvaGreen® Supermix (BioRad)

- GoTaq® qPCR Master Mix (Promega)



- **qPCR (commercially available)**

- KAPA Library Quantification Kit (Roche)

- QIAseq Library Quant Array (Qiagen)

- NEBNext® Library Quant Kit for Illumina® (NEB)

- qPCR NGS Library Quantification Kit (Agilent)





What are the options for performing sequencing?



MiSeq™ System (Illumina)



NextSeq™ System (Illumina)



Ion PGM™ System (Thermo Fisher Scientific)



MiniSeq™ System (Illumina)



GeneReader NGS System (Qiagen)





Ion S5™ System (Thermo Fisher Scientific)






Comparison of two different platforms in 2012/13: sequencing of **homopolymeric** regions

MiSeq





Other platform





MiSeq (Illumina)



Flow cell

MiSeq cartridge

- **Evaluation of sample quality/quantity**

- DNA concentration (Qubit/qPCR)
- Fragment size (PCR/Library)


- **Separation of pre- and post working areas**

- **Within-run controls**

- Negative control (without DNA)
- Negative control (with extraction reagents, when lot- no. changes)
- Change of barcodes between runs

- **Control of run parameters**


- Quality of base calling (Q30 Score)
- Cluster density (CD)
- Cluster passing filter (CPF)
- Coverage (≥ 200)
- Allele frequency ($\geq 5\%$ for mutation calling)



Underclustered ————— Optimal Clustering —————> Overclustered



Can you detect exon duplications and deletions of the BRCA1/2 genes in sporadic ovarian cancer samples?




Exon duplications and deletions of the *BRCA1/2* genes in sporadic ovarian cancer?

Walsh et al. JAMA 2006

MLPA technology

1. Denaturation and Hybridization



2. Ligation




3. PCR with universal primers X and Y

exponential amplification of ligated probes only



4. Fragment analysis



Statement from MCR-Holland

Is it possible to use DNA extracted from paraffin coupes for MLPA?

Yes. You can download a protocol for DNA extraction from formaldehyde-treated, paraffin-embedded tissues (FFPE) here. We have been notified that the extraction of DNA from paraffin by other methods did not always result in satisfactory results.

Blood


sample name	sample type	FMRS	X	Y	gender	analy...	CAS	PSLP	FSLP	RSQ	RPQ
P002 310 151014	sample		✓	●	female	☑		●	✓	✓	✓
P002 315 363093	sample		✓	●	female	☑		●	✓	✓	✓
P002 316 363094	sample		✓	●	female	☑		●	✓	✓	✓
P002 317 007077	sample		✓	●	female	☑		●	✓	✓	✓
P002 319 228018	sample		✓	●	female	☑		●	✓	✓	✓
P002 320 173012	sample		✓	●	female	☑		●	✓	✓	✓
P002 329 363099	sample		✓	●	female	☑		●	✓	✓	✓
P002 333 232027	sample		✓	●	female	☑		●	✓	✓	✓
P002 334 031006	sample		✓	●	female	☑		●	✓	✓	✓
P002 336 363095	sample		✓	●	female	☑		●	✓	✓	✓
P002 339 363101	sample		✓	●	female	☑		●	✓	✓	✓
P002 343 075007	sample		✓	●	female	☑		●	✓	✓	✓
P002 344 151015	sample		✓	●	female	☑		●	✓	✓	✓
P002 345 151016	sample		✓	●	female	☑		●	✓	✓	✓
P002 346 151018	sample		✓	●	female	☑		●	✓	✓	✓

FFPE


sample name	sample type	FMRS	X	Y	gender	analy...	CAS	PSLP	FSLP	RSQ	RPQ
P087 M11.37 1d alles	sample		✓	●	female	☑		●	✓	●	●
P087 M14.38 2 OT	sample		✓	●	female	☑		●	✓	●	●
P087 M92P	sample		✓	●	female	☑		●	✓	●	●
P087 M110.15 Tu	sample		✓	●	female	☑		●	✓	●	●
P087 M110P	sample		✓	●	female	☑		●	✓	●	●
P087 M173P	sample		✓	●	female	☑		●	✓	●	●
P087 M291P	sample		✓	●	female	☑		●	✓	●	●
P087 M371P	sample		✓	●	female	☑		●	✓	●	●
P087 O12P	sample		✓	●	female	☑		●	✓	●	●
P087 O21P	sample		✓	●	female	☑		●	✓	●	●
P087 O71P	sample		✓	●	female	☑		●	✓	●	●
P087 O136P	sample		✓	●	female	☑		●	✓	●	●
P087 O162P	sample		✓	●	female	☑		●	✓	●	●

- ▶ **High quality:** acceptable without reviewing.
- ▶ **Low quality:** failed samples → unsuitable, REJECT.
Coffalyser.Net gives information to solve root cause
- ▶ **Intermediate-quality:** view data and recommendations to improve results.

- ▶ Preliminary signal sloping (PSLP)
- ▶ Final signal sloping (FSLP)
- ▶ Reference sample quality (RSQ)
- ▶ Reference probe quality (RPQ)
- ▶ Coffalyser analysis score (CAS)









What are the most important pieces of advise you can give to someone starting *BRCA* tumour testing?



- Correct estimation of tumour cell content and highlighting of the tumour area
- Precise macrodissection with new scalpel for each case → avoid cross contamination
- Choose a DNA extraction method with good DNA quality and quantity that works well in downstream applications
- Negative control (no DNA) running alongside samples through library preparation and sequencing
- Correct handling of beads during purification steps
- Barcodes should be changed between runs
- The amplicon coverage $> 200x$
- Allelic fraction of mutation $> 5\%$
- Validating the whole process from DNA extraction to data interpretation as a whole

**It is important to choose 1 method, with which you have good experience.
Validate the chosen method and then use only this validated method!**

Institute of Pathology, Cologne

Reinhard Büttner

Jana Fassunke

Michaela A. Ihle

Birgid Markiefka

Sabine Merkelbach-Bruse

Roberto Pappesch

Jan Rehker

Janna Siemanowski

Svenja Wagener



Molecular Pathology Diagnostics Team
of Sabine Merkelbach-Bruse